Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.
Medically reviewed by Forest Miller, OTR/L When you are managing metastatic breast cancer, planning for the future is both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback